Ascendis Pharma ASASND +0.14%37 Gross Margin % is 92.90% as of Mar. 2026, which is 11% above its 10-year median of 83.36. GuruFocus rates ASND with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 738 Biotechnology companies, Ascendis Pharma AS ranks better than 83.06% on this metric.
The historical rank and industry rank for Ascendis Pharma AS's Gross Margin % or its related term are showing as below:
ASND'
s Gross Margin % Range Over the Past 10 Years
Min: 54.7 Med: 83.36 Max: 89.05
Current: 89.05
During the past 13 years, the highestGross Margin % of Ascendis Pharma AS was 89.05%. The lowest was 54.70%. And the median was 83.36%.
ASND's Gross Margin % is ranked better than 83.06% of 738
companies
in the Biotechnology industry
Industry Median: 60.94
vs ASND: 89.05
Ascendis Pharma AS had a gross margin of 92.90% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Ascendis Pharma AS was 0.00% per year.
Ascendis Pharma AS (NAS:ASND) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Ascendis Pharma AS had a gross margin of 92.90% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Ascendis Pharma AS Gross Margin % Related Terms
Ascendis Pharma AS Gross Margin % Historical Data
* Premium members only.
The historical data trend for Ascendis Pharma AS's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASND vs SMMT, BBIO, JAZZ: Gross Margin % Comparison
For the Biotechnology subindustry, Ascendis Pharma AS's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Ascendis Pharma AS (ASND) has a Gross Margin % of 92.90% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Ascendis Pharma AS and its competitors. This is 11% above median its historical median of 83.36. Over the past decade, Ascendis Pharma AS's Gross Margin % has ranged from 54.70 to 89.05. According to the industry distribution chart, Ascendis Pharma AS ranks #125 out of 738 companies in the Biotechnology industry, placing it in the top 16.9%.
Is Ascendis Pharma AS's Gross Margin % too high?
Ascendis Pharma AS's current Gross Margin % of 92.90% is 11% above median its 10-year median of 83.36. Over the past 10 years, this metric has ranged from a low of 54.70 to a high of 89.05. The Biotechnology industry median Gross Margin % is 60.94. Ascendis Pharma AS's value of 92.90% is 52.4% above this industry median. Based on the distribution chart, Ascendis Pharma AS ranks #125 out of 738 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Gross Margin % compare to SMMT and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #125 out of 738 companies for Gross Margin %. This places Ascendis Pharma AS in the top 17% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.94. Ascendis Pharma AS's value of 92.90% is 52.4% above this benchmark. Historically, Ascendis Pharma AS's own Gross Margin % has ranged from 54.70 to 89.05 over the past decade. While the company's 10-year median is 83.36 vs. the industry median of 60.94, Ascendis Pharma AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascendis Pharma AS's current Gross Margin % of 92.90% is 52.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Ascendis Pharma AS and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Pharma AS's current Gross Margin % is 92.90%, which is 11% above median its own 10-year median of 83.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current Gross Margin % of 92.90%. The current Gross Margin % is 92.90%, which is 11% above median its 10-year median of 83.36 and 52.4% above the Biotechnology industry median of 60.94. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current Gross Margin % is 92.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score
Get the complete analysis for ASND
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASND has been successfully added to your 
